Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Intensive Care Med , 1999
Innovative drugs to treat depression : did animal models fail to be predictive or did clinical trials fail to detect effects
35 Alpha-Glucosidase Inhibitors: These agents (e.g., acarbose, miglitol) work by reducing the rate of polysaccharide digestion from the gut and have been shown to augment incretin secretion
Several important considerations apply: Individuals with active or severe gastrointestinal disease may experience worsening symptoms due to the gastrointestinal side effects of GLP-1 medications The slowed gastric emptying caused by these drugs could theoretically exacerbate symptoms in people with strictures or obstructive complications of Crohn's disease Weight loss associated with GLP-1 therapy may be inappropriate in patients with Crohn's disease who are already experiencing malnutrition or unintentional weight loss The interaction between GLP-1 medications and the inflammatory processes in IBD is not fully understood Clinical decision-making should involve a thorough assessment of disease activity, nutritional status, presence of complications (such as strictures or fistulas), and the primary indication for GLP-1 therapy
Users who implement multiple management strategies simultaneously tend to navigate this phase more successfully than those who try to tough it out without support
We offer expert legal guidance to ensure that your practice and pharmacy remain compliant with FDA regulations and are ready for any future changes
